New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H, Kilifi, Kenya, March–May 2023
Mike J. Mwanga
1, Arnold W. Lambisia
1, John Mwita Morobe
1, Nickson Murunga
1, Edidah Moraa, Leonard Ndwiga, Robinson Cheruiyot, Jennifer Musyoki, Martin Mutunga, Laura M. Guzman-Rincon, Charles Sande, Joseph Mwangangi, Philip Bejon, Lynette Isabella Ochola-Oyier, D. James Nokes, Charles N. Agoti, Joyce Nyiro, and George Githinji
Author affiliations: Kenya Medical Research Institute Wellcome Trust Research Programme, Kilifi, Kenya (M.J. Mwanga, A.W. Lambisia, J.M. Morobe, N. Murunga, E. Moraa, L. Ndwiga, R. Cheruiyot, J. Musyoki, M. Mutanga, C. Sande, J. Mwangangi, P. Bejon, L.I. Ochola-Oyier, D.J. Nokes, C.N. Agoti, J. Nyiro, G. Githinji); University of Warwick, Coventry, UK (L.M. Guzman-Rincon, D.J. Nokes); Pwani University, Kilifi (C.N. Agoti, G. Githinji)
Main Article
Figure
Figure. Number of positive samples, distribution, and growth rate for new SARS-CoV-2 Omicron variant with spike protein mutation Y451H, Kilifi, Kenya, March–May 2023. The x axes indicate calendar weeks beginning on January 1, 2023. A) Weekly number of collected samples (black data line) and positive SARS-CoV-2 cases (data bars) in health facilities within the KHDSS during January–May 2023. Vertical dotted lines indicate the weeks when the FY.4 lineage was first detected in Kenya (red) and Kilifi (black). B) Weekly distribution of SARS-CoV-2 lineages observed in samples processed at the Kenya Medical Research Institute Wellcome Trust Research Programme from KHDSS (red dots) and non-KHDSS (blue dots) health facilities during January–May 2023. C) Growth rate estimates for the Omicron FY.4 variant in Kenya relative to those in the United States and Germany. KHDSS, Kilifi Health Demographic Surveillance System.
Main Article
Page created: August 31, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.